Home › Sudden Cardiac Arrest › NCT06401707

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥18 years old
* Non-traumatic, out-of-hospital cardiac arrest
* Comatose on admission - defined as not following commands
* Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
* Admission to the intensive care unit at Zuckerberg San Francisco General Hospital

Exclusion Criteria:

* Acute cerebral hemorrhage or infarction
* Pregnancy
* Prisoner
* Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
* Severe liver impairment with liver function tests five times above the upper limit of normal
* Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest

About the study

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

What is being tested

• Perampanel (drug)
• Placebo (drug)

Sponsor: University of California, San Francisco · Participants: 52 · Started: May 20, 2024

Contact the study team

• Edilberto Amorim, MD · Phone: 628-206-3203

Official record on ClinicalTrials.gov — NCT06401707

Locations in the U.S.

Conditions

• Sudden Cardiac Arrest
• Seizures
• Status Epilepticus

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.